Pharmacokinetics-Pharmacodynamics of Tazobactam in Combination with Ceftolozane in an In Vitro Infection Model

Despite β-lactamase inhibitors being available for clinical use for nearly 30 years, a paucity of data exists describing the pharmacokinetic-pharmacodynamic (PK-PD) determinants of efficacy for these agents. Herein, we describe dose fractionation studies designed to determine the exposure measure mo...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: VanScoy, Brian, Mendes, Rodrigo E., Nicasio, Anthony M., Castanheira, Mariana, Bulik, Catharine C., Okusanya, Olanrewaju O., Bhavnani, Sujata M., Forrest, Alan, Jones, Ronald N., Friedrich, Lawrence V., Steenbergen, Judith N., Ambrose, Paul G.
Format: Artigo
Langue:Inglês
Publié: American Society for Microbiology 2013
Sujets:
Pharmacology
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC3716129/
https://ncbi.nlm.nih.gov/pubmed/23629705
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.02513-12
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires